Pulmonary specialist health coach consultation model: a randomized controlled trial.

Ann Am Thorac SocOct 1, 2026
Clinical ResearchPulmonology

Rachel Willard-Grace, Abby Cabrera, Stephanie Tsao et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated a pulmonary specialist health coach consultation model for low-income patients with asthma and/or COPD. The intervention group received 1.61-fold more guideline-based care compared to the control group. The study highlights the potential of this model to enhance care in resource-limited settings.

Key findings

  • Intervention participants received 1.61-fold more guideline-based care than control participants.
  • No significant difference in guideline-based medications was found in the planned analysis.
  • Intervention patients reported greater improvements in breathing-related quality of life and symptoms.
  • More chronic lung disease education was provided to intervention participants.

Why it matters

Improving access to guideline-based care for socioeconomically disadvantaged patients with asthma and COPD is crucial for enhancing health outcomes. This model may help bridge care gaps in resource-limited settings.

Source

PubMed · PMID 42150017

Published in Ann Am Thorac Soc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.